Navigation Links
NOVAVAX Reports Fourth Quarter and 2010 Year-End Financial Results
Date:3/28/2011

ification from U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (HHS BARDA) that the Company's proposal to provide recombinant influenza vaccine products and manufacturing capabilities for pandemic preparedness was in the competitive range for award of an advanced development contract ($179 million contract award was announced subsequently in February 2011)
  • Reported positive clinical results from first-stage of 2009 H1N1 vaccine trial in Mexico (final results were presented in February 2011 at World Health Organization conference in Geneva)
  • Reported positive clinical results from Phase II seasonal influenza vaccine study in older adults
  • Completed construction and initiated validation testing of state-of-the-art vaccine production facility in India under the Company's joint venture with Cadila Pharmaceuticals
  • Received FDA clearance and initiated launch of a Phase I clinical trial in respiratory syncytial virus (RSV)
  • Published safety and efficacy findings from multiple pre-clinical studies supporting development of RSV vaccine based on virus-like particles
  • Received a key U.S. patent covering technology for rapid, efficient and uniform production of VLP-based vaccines against current and future strains of seasonal and pandemic influenza
  • Elected Stanley C. Erck as Executive Chairman of the Board of Directors and Richard H. Douglas, Ph.D. and James F. Young, Ph.D. as new Board of Director members
  • Awarded nearly $1 million in grants under the Internal Revenue Service's Therapeutic Discovery Project to support the development of VLP-based vaccines
  • Announced promotions of manufacturing managers and appointment of new Chief Medical Officer

  • Anticipated events in 2011:

  • Launch Phase II trial of seasonal influenza vaccine (under HHS BARDA contract)
  • Report top-line clinical data from Phase I RSV trial
  • Develop manuf
    '/>"/>

  • SOURCE Novavax, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
    2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
    3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
    4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
    5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
    6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
    7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
    8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
    9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
    10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
    11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
    (Date:7/30/2015)... York , July 30, 2015 ... its latest report titled, "Continuous Glucose Monitoring Systems Market: ... According to the report, the global continuous glucose monitoring ... 2014 and is expected to reach US$ 788.4 Mn ... forecast period, 2015 to 2020. Global continuous ...
    (Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
    Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
    ... The National Community Pharmacists Association (NCPA) expressed strong ... launched by the U.S. Senate Special Committee on ... Pharmalot . (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ... response, NCPA President Joseph H. Harmison, PD and Arlington, ...
    ... premier provider of economic ultrasound solutions, today announced the ... proprietary repair technology not previously available in the U.S. ... repair services designed to counter a growing emphasis in ... industry has been moving away from repairing customers, probes ...
    Cached Medicine Technology:NCPA Commends Senate Aging Committee for Launching CVS Caremark Investigation to Examine Alleged Harm to Seniors, Medicare 2MedPro Imaging Launches Ultrasound Transducer Repair Division 2
    (Date:7/31/2015)... ... ... Girl Scouts of Historic Georgia and Peach State Health Plan are teaming ... Friend First" program. Representatives from Peach State Health Plan presented a $10,000 check for ... our parent company, Centene Corporation, are dedicated to raising anti-bullying awareness. We are very ...
    (Date:7/31/2015)... , ... July 31, 2015 , ... The 2015 ALS ... Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders Pat Quinn ... MLB is donating $100,000 to further collaborative efforts among the ALS organizations to find ...
    (Date:7/31/2015)... Toledo, Ohio (PRWEB) , ... July 31, 2015 ... ... U.S. District Court for the Northern District of Ohio, Western Division (Case No. ... complaint (Case No: 3:15-cv-00397), the women experienced spontaneous migration of their Implanon® implants, ...
    (Date:7/31/2015)... NY and Rockport, ME (PRWEB) , ... July 31, 2015 , ... The alarm was ... op. , Glancing out of the window, he recalled that his equipment was set ... Chrystie Street tower, he jumped out of bed. , The photo speaks for itself. ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Patients with higher levels ... a study published today in Nature Communications and led by researchers from the Icahn ... that variations in the gene RTN1 led to greater production of the related RNT1 ...
    Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3
    ... GPRO ) announced today that the Company will release ... 2008 at approximately,4:00 p.m. Eastern Time (ET). The announcement ... ET. Henry L. Nordhoff, chairman and chief,executive officer, and ... will host the call., The conference call will ...
    ... of $350K will Target Easter Seals Affiliates Nationwide, ... the emerging,challenges of people living with autism during April,s ... $350,000 in grants this,month from the CVS Caremark Charitable ... million to support Easter Seals autism services,nationwide. These grants ...
    ... heart, lungs and liver, study suggests , , THURSDAY, April ... fatty plaques that harden arteries may also harm vital ... formation in arteries," said study author Rita K. Upmacis, ... at Weill Medical College of Cornell University in New ...
    ... Decline Even Though Everyone Benefits ... Forget to Claim The Deduction!, NEW YORK, April 10 ... a timely reminder that donating your car is,still a great way ... that because the number of vehicle donations has plummeted -- and,charities ...
    ... with this method, researchers find , , THURSDAY, ... and vegetables can reduce the risk of food ... bacteria, new research shows. , The study suggests ... the U.S. Food and Drug Administration, can kill ...
    ... NEW YORK, April 10 Methodist Healthcare -- Memphis,Hospitals ... tender offer for certain designated maturities of the,Bonds. The ... was set to,expire on April 9, 2008 at 5:00 ... the tender offer will be terminated is applicable to,the ...
    Cached Medicine News:Health News:Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call 2Health News:Easter Seals Receives $1 Million Donation From CVS Caremark Charitable Trust to Enhance Autism Services for Children 2Health News:Easter Seals Receives $1 Million Donation From CVS Caremark Charitable Trust to Enhance Autism Services for Children 3Health News:Atherosclerosis May Also Harm Vital Organs 2Health News:Atherosclerosis May Also Harm Vital Organs 3Health News:Tax Season Reminder: Vehicle Donations Still Needed 2Health News:Irradiation Almost Erases Risk of Food Poisoning 2Health News:Irradiation Almost Erases Risk of Food Poisoning 3Health News:Irradiation Almost Erases Risk of Food Poisoning 4Health News:Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers 2
    Curved tying forceps made of titanium has curved shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 103 mm....
    Curved tying spring forceps made of titanium, delicate smooth jaws, length 10 mm, TCI jaws with round handle, diam. 8 mm and overall length 115 mm....
    Thornton titanium curved suture tying forceps, 4"....
    Round handle McPherson angled tying forceps with 10 mm tips and 5 mm titanium coated platforms. Length 110 mm....
    Medicine Products: